| Message:
J'ai fait une rapide recherche dans scifinder sur le "liposomes targetting". Pour "lentivirus", il y a 7000 articles cités, je crois que cela fait beaucoup pour coller sur le forum. :o)
Research Topic task started on Fri Jun 20, 2003 at 9:34 AM
2 Research Topic candidates were identified in CAPLUS and MEDLINE.
using the phrase "liposomes targetting"
Selected 2 of 2 candidate topics.
3 references were found containing "liposomes targetting" as entered.
45 references were found containing the concept "liposomes targetting".
Copyrights:
Copyright 2003 ACS (The UK patent material in this product/service is UK Crown copyright and is made available with permission. (C) Crown Copyright. The French (FR) patent material in this product/service is made available from Institut National de la Propriete Industrielle (INPI).) for database CAPLUS
Produced by the U.S. National Library of Medicine for database MEDLINE
Copyright 2003 ACS (Some records contain information from GenBank(R). See also: Benson D.A., Karsch-Mizrachi I., Lipman D.J., Ostell J., Rapp B.A., Wheeler D.L. Genbank. Nucl. Acids Res. 28(1):15-18 (2000). Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.) for database REGISTRY
Copyright 2003 ACS (Some records from 1974 to 1991 are derived from the ZIC/VINITI data file provided by InfoChem. Some records are produced using some INPI data from the period prior to 1986.) for database CASREACT
Copyright 2003 ACS for databases CHEMCATS and CHEMLIST
Bibliographic Information
Disposition kinetics of ketotifen from liposomal dry powder for inhalation
in rat lung. Joshi, Mayank; Misra, Ambikanandan. Pharmacy
Department, Faculty of Technology and Engineering, MS University of
Baroda, Baroda, India. Clinical and Experimental Pharmacology and
Physiology (2003), 30(3), 153-156. CODEN: CEXPB9 ISSN: 0305-1870.
Journal written in English. AN 2003:236914 CAPLUS (Copyright 2003
ACS)
Abstract
1. The aim of the present study was to understand the benefit of liposomal
dry powder for inhalation (LDPI) of ketotifen fumarate (KF) over plain drug
dry powder for inhalation as a pulmonary targetted drug-delivery system.
2. The KF liposomes, composed of egg phosphatidyl choline and cholesterol,
were prepd. by the lipid film hydration technique. The liposomal
dispersion was freeze dried and formulated to a dry powder for inhalation.
Values of 89.0-65.3% drug entrapment of freeze-dried liposomes were estd.
in prepd. batches. 3. Rehydrated KF liposomes formed by the hydration of
LDPI or the plain KF soln. was delivered to rat lungs by intratracheal
instillation. Simultaneous monitoring of drug levels in the
bronchoalveolar lavage and lung tissue enabled assessment of pulmonary drug
disposition. 4. Cumulative drug levels in lung tissue after intratracheal
administration revealed that with liposomes targetting factors were between
1.36 and 1.54. The maximal drug concn. in lung homogenate for LDPI was
42.0 .mu.g compared with 73.6 .mu.g for plain drug soln. 5. Similarly, the
time to reach max. drug concn. in the lung homogenate for liposomal dry
powder was 9-12 h compared with 3 h for plain drug. 6. Hence, the use of
LDPI of KF was found to provide desired drug levels in the lung for a long
time and thereby increased pulmonary targetting. 7. This is expected to
enhance the therapeutic index of the drug and probably reduce the dose
administered and the cost of therapy.
Bibliographic Information
Preparation of liposomes carrying organ, tumor and leukemia - specific
oligosaccharide haptens and usage for drug targeting. Pascoe, Peter F.
(Germany). Ger. Offen. (2002), 4 pp. CODEN: GWXXBX DE 10055701
A1 20020508 Patent written in German. Application: DE 2000-10055701
20001102. CAN 136:345829 AN 2002:347255 CAPLUS (Copyright 2003
ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
DE 10055701 A1 20020508 DE 2000-10055701 20001102
Priority Application Information
DE 2000-10055701 20001102
Abstract
The invention concerns the prepn. of liposomes in aq. mixts. of lipids,
phospholipids, cholesterol and a glycolipid that contains an
oligosaccharide with a fraction (oligosaccharide hapten) that is identical
to a target cell surface; the liposomes are used for the delivery of drugs
included in the liposomes to the targetted cells, e.g. tumor and leukemia
cells. The various active substances that can be incorporated in the
liposomes are enzymes, hormones, antibiotics, antigens, DNA, RNA, also
loaded in viruses, phages, etc.
Bibliographic Information
In vivo myocardial gene transfer: Optimization, evaluation and direct
comparison of gene transfer vectors. Wright, Matt J.; Wightman, Lionel
M. L.; Lilley, Caroline; de Alwis, Mahesh; Hart, Steven L.; Miller, Andrew;
Coffin, Robert S.; Thrasher, Adrian; Latchman, David S.; Marber, Michael S.
Department of Cardiology, KCL The Rayne Institute, St. Thomas'
Hospital, London, UK. Basic Research in Cardiology (2001), 96(3),
227-236. CODEN: BRCAB7 ISSN: 0300-8428. Journal written in English.
CAN 136:161928 AN 2001:427574 CAPLUS (Copyright 2003 ACS)
Abstract
The purpose was to det. the relative efficiency, toxicity and duration of
expression following gene delivery by intramyocardial injection of naked
DNA, naked DNA complexed to cationic liposomes, naked DNA complexed to
cationic liposomes with integrin-targetting peptide, recombinant (E1/E3)
adenovirus, recombinant adeno-assocd. virus and recombinant (ICP27-) herpes
simplex virus. All vectors incorporated a LacZ reporter driven by a
promoter contg. the hCMV-IE promoter/enhancer. Efficiency was scored by
counting pos. cells in five std. microscopic sections harvested from the
left ventricular apex. Rabbit hearts (n = 100) were examd. from 2 to 56
days after injection. Uncomplexed and complexed naked DNA were very
inefficient with less than one pos. cell visible per heart. The viral
vectors all resulted in robust gene expression with adenovirus being the
most efficient by at least one order of magnitude before 21 days. However,
despite disparate titers, the efficiency beyond 21 days of adenovirus and
adeno-assocd. virus were comparable. In contrast to adeno-assocd. virus,
both adenovirus and herpes-simplex virus were assocd. with a marked
inflammatory response. Despite reporter gene activity appearing only after
21 days, adeno-assocd. virus shows comparative promise as a myocardial gene
delivery vector.
Bibliographic Information
Galactosylated liposomes as carriers for targeting
meso-2,3-dimercaptosuccinic acid to cadmium storage sites in cadmium
exposed mice. Behari, Jai Raj; Nihal, Minakshi. Industrial
Toxicology Research Centre, Lucknow, India. Industrial Health (2000),
38(4), 408-412. CODEN: INHEAO ISSN: 0019-8366. Journal written in
English. CAN 134:189120 AN 2000:810070 CAPLUS (Copyright 2003
ACS)
Abstract
In this study an attempt has been made to examine the efficacy of
meso-2,3-dimercaptosuccinic acid (DMSA) using galactosylated liposomes as
carriers for mobilization of cadmium from the body of mice preexposed to
cadmium chloride (0.005 mmoles/kg i.p. daily for 4 days). Cadmium-exposed
mice after a rest period of 8 wk were administered DMSA i.v., two
injections 15 .mu.moles/kg with an interval of 48 h, as free form of DMSA,
or DMSA encapsulated in liposomes composed of phosphatidylcholine,
cholesterol and phosphatidylethanolamine (7:2:1; PC-lip-DMSA) or in
liposomes to which p-aminophenyl galactoside had been anchored
(Gal-lip-DMSA). Excretion of cadmium through urine and feces was monitored
for 5 days. Thereafter animals were sacrificed, liver, kidneys, spleen and
isolated hepatocytes were analyzed for cadmium, copper and zinc concn.
Efficacy for cadmium mobilization from the body was found to be in the
order Gal-lip-DMSA>PC-lip-DMSA>DMSA. These results show that liposomes can
be used as targeted carrier system for chelating agents safely and
efficiently as compared to administration of free chelating agent.
Bibliographic Information
Fusion proteins of viral surface proteins and ligands for LDL receptor
superfamily members for targetting of materials to specific cell types.
Rosenberg, Steven. (Chiron Corporation, USA). PCT Int. Appl. (1997),
44 pp. CODEN: PIXXD2 WO 9724453 A1 19970710 Designated States W:
CA, JP, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM. Patent written in English.
Application: WO 96-US19196 19961202. Priority: US 95-580139. CAN
127:105243 AN 1997:510223 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9724453 A1 19970710 WO 1996-US19196 19961202
W: CA, JP, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 880596 A1 19981202 EP 1996-946385 19961202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001519647 T2 20011023 JP 1997-524326 19961202
Priority Application Information
US 1995-580139 19951228
WO 1996-US19196 19961202
Abstract
A method of displaying ligands for cell type-specific receptors on the
surface of a virus or a non-viral particle such as a liposome using fusion
proteins of the ligand and a viral surface protein is described.
Specifically, ligands for member of the LDL receptor family are used.
Particles carrying these fusion proteins can be internalized by the target
cells for delivery of nucleic acids. Examples include fusion proteins of a
serpin, for example PAI-1, for targeting cells presenting urokinase
receptor with bound urokinase. Cell specific gene therapy is possible
using these methods and materials.
Bibliographic Information
Cationic polyacrylates and poly(alkyl) acrylates and acrylamides for use as
carriers of nucleic acid in the transformation of animal cells.
Hennink, Wilhelmus Everhardus; Van De Wetering, Petra. (Octoplus B.V.,
Neth.; Hennink, Wilhelmus, Everhardus; Van De Wetering, Petra). PCT Int.
Appl. (1997), 37 pp. CODEN: PIXXD2 WO 9715680 A1 19970501
Designated States W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM. Designated States RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG. Patent written in English.
Application: WO 96-NL416 19961025. Priority: EP 95-202891; US 95-5923.
CAN 127:1631 AN 1997:389223 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9715680 A1 19970501 WO 1996-NL416 19961025
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG
AU 9673422 A1 19970515 AU 1996-73422 19961025
EP 859857 A1 19980826 EP 1996-935575 19961025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI,
LT, LV, FI, RO
JP 2001508641 T2 20010703 JP 1997-516497 19961025
US 5985573 A 19991116 US 1998-67276 19980427
Priority Application Information
EP 1995-202891 19951025
US 1995-5923P 19951027
WO 1996-NL416 19961025
Abstract
Cationic, water sol. or water dispersible polyacrylates, polyacrylamides,
poly(C1-6 alkyl)acrylates, or poly(C1-6 alkyl)acrylamides are described as
carriers for nucleic acids in the transformation of animal cells, e.g. in
gene therapy. These complexes may be incorporated into liposomes or
hydrogels and be used with targetting moieties such as monoclonal
antibodies. Fusogenic agents may also be incorporated into the complex.
Homo- and co-polymers of dimethylaminoethyl methacrylate were prepd. by
std. chem. Optimization expts. using the lacZ gene-carrying plasmid
pCMVlacZ and the homopolymer to transform COS cells showed that the
homopolymer led an .apprx.100-fold increase of efficiency of transformation
of COS cells. Toxicity to the recipient cells was comparable to that of
polylysine.
Bibliographic Information
Controlled cancer effects of artificial cell films. Ueoka, Ryuichi;
Matsumoto, Yoko; Imamura, Chikara. Kumamoto Inst. of Technol., Japan.
Kemikaru Enjiniyaringu (1997), 42(1), 33-39. CODEN: KEENAT ISSN:
0387-1037. Journal; General Review written in Japanese. CAN 126:249492
AN 1997:154271 CAPLUS (Copyright 2003 ACS)
Abstract
A review with 8 refs., on proliferation inhibition against lymphoma-a novel
antitumor mechanism, organ-targetting liposome, and animal model for brain
tumor treatment.
Bibliographic Information
Experimental efficacy of targetting PEG-liposomes encapsulating
amphotericin B. Otsubo, T.; Koga, H.; Tanaka, E.; Takizawa, T.;
Maruyama, K.; Kohno, S. School of Medicine, Nagasaki Univ., Nagasaki,
Japan. Proceedings of the International Symposium on Controlled Release
of Bioactive Materials (1996), 23rd 677-678. CODEN: PCRMEY ISSN:
1022-0178. Journal written in English. CAN 125:230399 AN
1996:522364 CAPLUS (Copyright 2003 ACS)
Abstract
In an exptl. model of invasive pulmonary aspergillosis, the effects of
functional liposomal amphotericin B were satisfactory for targetability and
therapy.
Bibliographic Information
Free versus liposome-entrapped streptomycin sulfate in treatment of
infections caused by Salmonella enteritidis. Khalil, R. M.; Murad, F.
E.; Yehia, S. A.; El-Ridy, M. S.; Salama, H. A. Dep. Pharm. Sci., Cairo
Univ., Cairo, Egypt. Pharmazie (1996), 51(3), 182-4. CODEN: PHARAT
ISSN: 0031-7144. Journal written in English. CAN 124:298726 AN
1996:182722 CAPLUS (Copyright 2003 ACS)
Abstract
Streptomycin sulfate (I) liposomes were prepd. by the vortex dispersion
method. The liposomes were formulated from a mixt. of
L-.alpha.-dipalmitoyl phosphatidyl choline (DPPC), cholesterol with or
without (neutral) a charge inducing agent. Two phospholipid molar ratios
were considered, namely, DPPC/cholesterol 7:2 and 7:4. The amt. of I
entrapped was estd., microbiol., and ranged from 0.080 - 1.323% of the
initial amt. of drug used for prepn. of liposomes. Particle size anal.,
measured by the coulter counter, showed a mean particle diam. from
4.417-8.424 .mu.m. Drug targeting expts. were done using Swiss mice as the
exptl. animals. The in-vivo results indicated that I concn. targeted to
the liver and spleen by the liposome encapsulated drug was 2-3 times that
exhibited by the free drug. This effect occurred after one day of liposome
injection, but it decreased over time from 1-7 days.. The amt. of I
targeted to the lung, by the liposome formulation 7:2:1 was more than that
exhibited by the free drug. This is true only after 7 d from injection.
On the other hand, the liposomes of molar ratio 7:4:1 showed much less
effect even when compared to the free drug. The survival rate expts.
indicated a definite protection against Salmonella enteritidis, exhibited
by the liposome-encapsulated I compared to the free drug.
Bibliographic Information
Liposome-entrapped antimicrobial agents for abdominal infection.
Bohnen, J.M.A. Wellesley Hospital, University of Toronto, Toronto,
ON, Can. Drug Targeting and Delivery (1995), 6 135-45. CODEN:
DTDEET ISSN: 1058-241X. Journal; General Review written in English.
CAN 124:185215 AN 1996:110769 CAPLUS (Copyright 2003 ACS)
Abstract
A review with 53 refs. Abdominal infection is a common, serious problem.
Conventional management consists of resuscitation, surgical or tube
drainage of the peritoneal cavity and systemic antimicrobial agents.
Antimicrobial therapy is intended to neutralize bacteria not reached by
surgical means. A rational for the use of liposomes-entrapped
antimicrobial agents in the treatment of abdominal infections. Exptl.
evidence demonstrates that in abdominal infection viable bacteria reside in
reticuloendothelial system (RES) mononuclear phagocytes which are not
targetted by conventional antimicrobial agents. A hypothesize is presented
that liposome-entrapped antimicrobial agents, by targetting mononuclear
phagocytes of the RES, will improve the outcome of infection.
Bibliographic Information
Functional elements of locus control regions that ensure the expression of
introduced genes independent of integration site. Ellis, James;
Grosveld, Franklin Gerardus; Kioussis, Dimitris. (Medical Research
Council, UK). PCT Int. Appl. (1995), 93 pp. CODEN: PIXXD2 WO
9533841 A1 19951214 Designated States W: AM, AT, AU, BB, BG, BR, BY, CA,
CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK,
LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, TJ, TM, TT. Designated States RW: AT, BE, CH, DE, DK, ES, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD,
TG. Patent written in English. Application: WO 95-GB1348 19950609.
Priority: GB 94-11618; US 95-488145. CAN 124:108962 AN 1996:87110
CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9533841 A1 19951214 WO 1995-GB1348 19950609
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE,
HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 6110666 A 20000829 US 1995-488145 19950607
AU 9526781 A1 19960104 AU 1995-26781 19950609
EP 765396 A1 19970402 EP 1995-921896 19950609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Priority Application Information
GB 1994-11618 19940609
US 1995-488145 19950607
US 1994-314657 19940929
WO 1995-GB1348 19950609
Abstract
A subregion of a mammalian locus control region (LCR) that possesses
chromatin domain opening activity is described. This region confers
reproducible activation of tissue-specific expression of a linked gene to a
non-physiol. low level when the gene is integrated in a single copy into
the genome of a host cell. When a complete LCR is used, expression reaches
full or near-physiol. levels. These elements can be used to improve the
reproducibility in transgenic animals and in gene therapy.
Chromatin-opening domains in the DNase I-hypersensitive sites of the human
.beta.-globin gene were mapped by their effects on gene expression in
transgenic mice and found to lie in 5'-HS3 but outside the core region and
no activity was assocd. with the enhancer-contg. sites 5'-HS2 or 5'-HS4.
Reporter gene methods for identifying LCRs that do, or do not, contain
these domains are described. Expression constructs using these domains for
gene therapy of Gaucher's disease and agammaglobulinemia are described.
Bibliographic Information
pH-dependent permeabilization of liposomes by poly(2-ethylacrylic acid).
Thomas, James L.; Chung, Johnson; Gross, David; Tirrell, David.
Department Polymer Science and Engineering, University Massachusetts,
Amherst, MA, USA. Book of Abstracts, 210th ACS National Meeting,
Chicago, IL, August 20-24 (1995), (Pt. 2), POLY-056. Publisher:
American Chemical Society, Washington, D. C CODEN: 61XGAC Conference;
Meeting Abstract written in English. AN 1995:925608 CAPLUS
(Copyright 2003 ACS)
Abstract
Controlling the structure and permeability of liposomal membranes is
essential in order to exploit their potential medical uses in targetted
drug delivery and genetic therapy. The simple synthetic polyelectrolyte,
poly(2-ethylacrylic acid) (PEAA), solubilizes phospholipid membranes in a
pH-dependent manner, when present at equal wt. concn. At much lower
polymer concns., PEAA does not cause solubilization, but instead forms
channels in the membrane that permit rapid transbilayer permeation of ions.
These channels were studied by patch-clamp techniques. Surprisingly, the
channels fluctuate rapidly between "open" and "closed" conductance states,
and often the "open" states have dicrete, reproducible conductance levels.
These results imply that the pores or channels formed by PEAA can have
well-defined sizes, in spite of the heterogeneity of the polymer.
Bibliographic Information
Growth/differentiation factor-6: a novel member of the transforming growth
factor .beta. associated with placental growth. Lee, Se-Jin; Huynh,
Thanh. (Johns Hopkins University School of Medicine, USA). PCT Int.
Appl. (1995), 61 pp. CODEN: PIXXD2 WO 9501801 A1 19950119
Designated States W: AU, CA, JP, US. Designated States RW: AT, BE, CH, DE,
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. Patent written in
English. Application: WO 94-US7762 19940708. Priority: US 93-89300.
CAN 122:257081 AN 1995:478330 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9501801 A1 19950119 WO 1994-US7762 19940708
W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2165776 AA 19950119 CA 1994-2165776 19940708
AU 9473593 A1 19950206 AU 1994-73593 19940708
AU 697625 B2 19981015
JP 09503903 T2 19970422 JP 1994-504197 19940708
EP 804214 A1 19971105 EP 1994-922520 19940708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
US 5770444 A 19980623 US 1996-581529 19960415
Priority Application Information
US 1993-89300 19930709
WO 1994-US7762 19940708
Abstract
Growth/differentiation factor-6 (GDF-6), a novel member of the TGF-.beta.
family assocd. with cell proliferation in the placenta is described along
with its amino acid sequence and the sequence of a cDNA encoding it. The
cDNA and the protein may be of use in the diagnosis and treatment of
abnormal growth and development of the placenta or other disorders (no
data). A partial cDNA for GDF-6 was cloned by PCR using primers derived
from sequences widely conserved in the TGF-.beta. family and the resulting
fragment used to screen a genomic bank for the gene. Northern blots showed
that the gene was expressed in the placenta in late gestation.
Bibliographic Information
A novel member of the transforming growth factor .beta. family: growth
differentiation factor-7. Lee, Se-Jin; Huynh, Thanh. (Johns Hopkins
University School of Medicine, USA). PCT Int. Appl. (1995), 59 pp.
CODEN: PIXXD2 WO 9501802 A1 19950119 Designated States W: AU, CA, JP,
US. Designated States RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE. Patent written in English. Application: WO 94-US7799
19940708. Priority: US 93-89670. CAN 122:257080 AN 1995:478329
CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9501802 A1 19950119 WO 1994-US7799 19940708
W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2165778 AA 19950119 CA 1994-2165778 19940708
AU 9473297 A1 19950206 AU 1994-73297 19940708
AU 688779 B2 19980319
EP 717633 A1 19960626 EP 1994-923432 19940708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 09503904 T2 19970422 JP 1994-504207 19940708
US 5986058 A 19991116 US 1996-581528 19960109
Priority Application Information
US 1993-89670 19930709
WO 1994-US7799 19940708
Abstract
Growth differentiation factor-7 (GDF-7), a novel member of the TGF-.beta.
superfamily of regulatory proteins is described along with its amino acid
sequence and the sequence of the gene encoding it. Diagnostic and
therapeutic uses of the DNA and the GDF-7 protein are disclosed. The
protein is assocd. with cell proliferation disorders in neural tissues and
so may be a target or therapeutic agent in the treatment of these diseases.
The gene for mouse GDF-7 was cloned by PCR using degenerate primers for
conserved regions of the TGF-.beta. superfamily. This was used as a probe
to obtain a full-length genomic clone. The transcript for the gene was
most abundant in fetal and neonatal brain and in the Neuro 2A neuroblastoma
cell line.
Bibliographic Information
A transcription factor binding site of the c-erbB-2 promoter and the
transcription factor as targets for the diagnosis and treatment of cancer.
Sikora, Karol; Hurst, Helen Catherine; Lemoine, Nicholas Robert;
Hollywood, Donal Patrick. (Imperial Cancer Research Technology Ltd., UK).
PCT Int. Appl. (1994), 98 pp. CODEN: PIXXD2 WO 9428127 A1
19941208 Designated States W: JP, US. Designated States RW: AT, BE, CH,
DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. Patent written in
English. Application: WO 94-GB1132 19940524. Priority: US 93-66297.
CAN 122:207018 AN 1995:422778 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9428127 A1 19941208 WO 1994-GB1132 19940524
W: JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
Priority Application Information
US 1993-66297 19930524
Abstract
The OB2-1 element of the promoter of the c-erbB-2 gene binds a
transcription activator and the element and the factor may be used as a
target for control of oncogenic c-erbB-2 gene expression in the treatment
of cancer. Antibodies reactive with the protein, and genes encoding OB2-1
and compds. interfering with the binding of OB2-1 to its binding site are
described. Measurement of the abundance OB2-1 in tumors may be used as a
prognostic marker and to indicate which tumors are suitable for treatment
with the DNA construct and compds. of the invention. A method using the
OB2-1-binding site as part of a promoter to drive tumor-specific expression
of a gene for a directly or indirectly cytotoxic gene product, such as
cytosine deaminase (CD), is described. CD converts the pro-drug
5-fluorocytosine into the more toxic 5-fluorouracil. Functional anal. and
footprinting studies of the promoter region of the c-erbB-2 gene identified
a region that was bound only by a factor from tumors that over-expressed
c-erbB-2. Purifn. of the OB2-1 protein and cloning of a cDNA encoding it
are described.
Bibliographic Information
Chemical radioprotection: thiols. Srivastava, P N.; Ayene, S I.; Misra,
V S. Nuclear Science Centre, Jawaharlal Nehru University Campus, New
Delhi, India. Proceedings of the Indian National Science Academy, Part
B: Biological Sciences (1994), 60(3), 197-215. CODEN: PIBSBB ISSN:
0073-6600. Journal; General Review written in English. CAN 121:275299
AN 1994:675299 CAPLUS (Copyright 2003 ACS)
Abstract
A review with about 100 refs. In spite of extensive research during the
last four decades, no ideal radioprotective drug for radiotherapy of cancer
has emerged. The radioprotectors tried so far have shown either low dose
modification factor (DMF) or high toxicity. Sulphydryl compds. are very
good radioprotectors but their application in radiotherapy is limited
because they lack the twin properties of low toxicity and high DMF.
Various classes of radioprotective compds., theories of chem. protection,
review of radioprotective effects of various drugs esp. WR 2721 and MPG
have been discussed. The drawbacks of drugs to differentially protect the
normal tissues esp. the side effects have been reviewed and indications for
further research work have been given to improve the efficacy of each
method. Possibilities of other drug delivery system using much lesser amt.
of radioprotective drugs and hence reducing the toxic effects of the drugs
such as trapping them with liposomes and then targetting them to resp.
sites have been shown. Further work in these areas is necessary.
Bibliographic Information
Influence of liposomal composition on topical delivery of encapsulated
cyclosporin A I. An in vitro study using hairless mouse skin. Dowton,
S.M.; Hu, Z.; Ramachandran, C.; Wallach, D.F.H.; Weiner, N. Univ.
Michigan, Ann Arbor, MI, USA. S.T.P. Pharma Sciences (1993), 3(5),
404-7. CODEN: STSSE5 ISSN: 1157-1489. Journal written in English.
CAN 120:173286 AN 1994:173286 CAPLUS (Copyright 2003 ACS)
Abstract
This study compares the efficiency of two test non-ionic liposomal
(NovasomeTM) formulations with more conventional liposomal compns. as to
their ability to facilitate cyclosporin A transport into and through the
skin as detd. by Franz diffusion studies using hairless mouse skin. The
extent of deposition of drug into the deeper skin strata is highly
dependent on the type of liposomal formulation used and the data presented
in this preliminary study clearly demonstrates that liposomes, esp.
NovasomesTM, can be customized to deliver their payloads to a targetted
layer of skin either rapidly or slowly from a stratum corneum assocd.
reservoir.
Bibliographic Information
Use of viral hulls containing antisense expression constructs for
inhibition of viral infection. Meyer, Frank Andreas Harald. (Germany).
PCT Int. Appl. (1993), 38 pp. CODEN: PIXXD2 WO 9322433 A2
19931111 Designated States W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DK, ES,
FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU,
SD, SE, SK, UA, US, VN. Designated States RW: AT, BE, CH, DE, DK, ES, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE,
SN, TD, TG. Patent written in German. Application: WO 93-DE374
19930428. Priority: WO 92-EP923; DE 92-4238879. CAN 120:24987 AN
1994:24987 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9322433 A2 19931111 WO 1993-DE374 19930428
WO 9322433 A3 19940707
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DK, ES, FI, GB, HU, JP, KP, KR, KZ,
LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9342591 A1 19931129 AU 1993-42591 19930428
EP 677103 A1 19951018 EP 1993-911729 19930428
R: CH, DE, ES, FR, GB, IT, LI
Priority Application Information
WO 1992-EP923 19920428
DE 1992-4238879 19921119
WO 1993-DE374 19930428
Abstract
Antisense expression constructs for the prevention of replication of a
virus or the expression of oncogenes in a host cell are introduced into the
target cells using viral hulls free of viral nucleic acid. The use of the
viral hulls ensures accuracy of delivery and also uses them to vaccinate
the host against the viral hull. The compn. is administered in liposomes
and is intended for use with animals and plants. Methods for the
construction of virus contg. the antisense construct are described.
Bibliographic Information
Application of molecular biology to the staff-processing technique.
Takebayashi, Hitoshi. Tokyo, Japan. Zairyo Gijutsu (1993), 11(7),
219-25. CODEN: ZAGIET ISSN: 0289-7709. Journal; General Review written
in Japanese. CAN 119:269044 AN 1993:669044 CAPLUS (Copyright
2003 ACS)
Abstract
A review with 35 refs. on the application of mol. biol. to the prodn. of
anticancer agents. Prodn. of monoclonal antibody-binding liposomes contg.
adriamycin (ADM) for targetting therapy and an example of an expt. using
this complex are introduced. Merits of uses of Fab' antibody-binding
liposome, examples of studies using stealth liposome and temp.-sensitive
liposome (Ts-Lip) are described. The effects of transferrin
(Tf)-anticancer agent complex, Tf-gene complex, and protein-bound (polymd.)
anticancer agent are also described.
Bibliographic Information
Studies on the tissue distribution of liposome-associated clofazimine, an
antileprosy drug. Sritharan, Manjula. Dep. Biochem., Univ. Delhi,
New Delhi, India. Methods and Findings in Experimental and Clinical
Pharmacology (1993), 15(2), 107-11. CODEN: MFEPDX ISSN: 0379-0355.
Journal written in English. CAN 119:85355 AN 1993:485355 CAPLUS
(Copyright 2003 ACS)
Abstract
Clofazimine, a potent antimycobacterial drug, being highly lipophilic
accumulates in fatty tissue and in the reticuloendothelial system causing
dose-dependent side effects. In this study, the distribution of the free
drug and liposome-assocd. drug was compared after i.v. administration in
mice. Differences in the distribution of the drug were obsd. in the liver,
spleen, kidney and lung tissues when injected as free drug and as
liposome-assocd. drug. Following i.v. challenge with the free drug, the
drug accumulated quickly and high concns. of the drug were seen in the
spleen, liver, kidney and lung even after 24 h, indicating poor clearance.
However, with liposome-assocd. drug, increased levels were seen in liver,
spleen and lung at 1 h with levels falling considerably at 24 h, with no
accumulation in the kidney either at 1 h or 24 h after challenge.
Clofazimine assocd. with neutral liposomes was preferentially targetted to
spleen and lung, pos. charged liposome-assocd. drug accumulated more in the
lungs than in other tissues, while neg. charged liposome-assocd. drug was
directed to liver and spleen. The results suggest that inclusion of
clofazimine into liposome not only targets the drug to the organs concerned
but also facilitates clearance of the drug, resulting in little
accumulation. Also, renal accumulation is much lower as compared to the
free drug. This suggests the potential usefulness of liposome as a carrier
for clofazimine, thereby reducing the harmful side effects due to excessive
accumulation of the drug.
Bibliographic Information
Liposome encapsulation enhances the efficacy of adriamycin to inhibit tumor
in vivo. Hu, Lanrong; Zhai, Yuan; Zheng, Changxue; Dong, Zhiwei.
Dep. Biol. Sci. Biotechnol., Tsinghua Univ., Beijing, Peop. Rep. China.
Shengwu Huaxue Zazhi (1993), 9(1), 76-80. CODEN: SHZAE4 ISSN:
1000-8543. Journal written in Chinese. CAN 118:219743 AN
1993:219743 CAPLUS (Copyright 2003 ACS)
Abstract
Adriamycin (ADM)-contg. targeted liposomes bearing monoclonal antibody 3Hll
against human gastric carcinoma M85 cells on their surface were prepd. by
sonication. The tissue distribution of ADM-entrapped liposomes and its
efficacy to inhibit tumor after injection i.p. into tumor-bearing nude mice
were investigated as compared with free ADM. The results indicated that
the content of ADM targeted liposomes in the tumor tissues was higher
apparently than free ADM. However, the content of the former was lower
than the latter in heart. Free ADM or targeted liposomes were injected
i.p. into nude mice (4 mg/Kg body wt.) at day 5, 13, and 25, and the data
were obtained at 40 days after inoculation of M85 cells. ADM targeted
liposomes were better than free ADM in some respects such as the incidence
of survival in the animals, the ratio of tumor occurrence and the rate of
tumor growth.
Bibliographic Information
Methods and substances for recruiting therapeutic agents to solid issues
comprising two single chain VH-VL bifunctional binding molecules. Tse,
Wang Chang. (Tanox Biosystems, Inc., USA). Eur. Pat. Appl. (1992),
15 pp. CODEN: EPXXDW EP 506124 A1 19920930 Designated States R: AT,
BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE. Patent
written in English. Application: EP 92-105380 19920327. Priority: US
91-675654. CAN 117:239854 AN 1992:639854 CAPLUS (Copyright 2003
ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
EP 506124 A1 19920930 EP 1992-105380 19920327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE
CA 2062582 AA 19920928 CA 1992-2062582 19920310
CA 2062582 C 19960326
AU 9212992 A1 19921015 AU 1992-12992 19920318
AU 640863 B2 19930902
ZA 9202017 A 19930331 ZA 1992-2017 19920319
JP 05117164 A2 19930514 JP 1992-101629 19920327
Priority Application Information
US 1991-675654 19910327
Abstract
Disclosed is a compn. for enhancing delivery of a therapeutic agent to a
solid tissue site, comprising: two single chain VH-VL bifunctional binding
mols., having one specificity for a solid tissue antigen and the other for
the therapeutic agent; a remover substance which binds circulating binding
mol.; a therapeutic agent. The therapeutic agent is administered sep. from
the binding mols., and a remover substance is administered which aids in
clearing free binding mols. in the circulation. The binding mols. have one
specificity for antigens at the target site and one for the therapeutic
agent. The binding mols. are administered and allowed time to approach a
max. concn. in the extravascular space. A remover substance, preferably a
liposome conjugated with antibodies which are reactive with an antigenic
epitope on the binding mols., is then administered to remove excess binding
mols. from the blood and the extravascular space. A therapeutic agent,
preferably a cytotoxic drug such as ricin A chain modified so as to enable
it to enter the target cells once delivered to the target site, is then
administered. The preferred target sites for the therapeutic agents are
solid tumors.
Bibliographic Information
Gelsolin-based fusion proteins for use in lipid vesicle drug delivery
systems. Pepinsky, R. Blake; Rosa, Margaret D.; Stossel, Thomas P.
(Biogen, Inc., USA). PCT Int. Appl. (1991), 28 pp. CODEN: PIXXD2
WO 9117170 A1 19911114 Designated States W: AU, BB, BG, BR, CA, FI, HU,
JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU, US. Designated States RW:
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, BF, BJ, CF, CG, CI, CM,
GA, ML, MR, SN, TD, TG. Patent written in English. Application: WO
91-US2954 19910503. Priority: US 90-520368. CAN 116:221563 AN
1992:221563 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9117170 A1 19911114 WO 1991-US2954 19910503
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD,
SU, US
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT,
LU, ML, MR, NL, SE, SN, TD, TG
CA 2063593 AA 19911105 CA 1991-2063593 19910503
AU 9180861 A1 19911127 AU 1991-80861 19910503
EP 481070 A1 19920422 EP 1991-910701 19910503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 05501503 T2 19930325 JP 1991-510402 19910503
Priority Application Information
US 1990-520368 19900504
WO 1991-US2954 19910503
Abstract
Fusion proteins contg. the lipid-binding domains of gelsolins are prepd.
for use in the targetted delivery of drugs in liposomes. The fusion
protein contains a second domain that targets the vesicle to the
appropriate tissue. Other actin- or phosphoinositide-binding proteins
similar to gelsolin may also be used. Fusion products of CD4 antigen and
gelsolin were prepd. by expression of a chimeric gene for the fusion
protein or by chem. crosslinking of the moieties. Crosslinking of the
moieties either via a derivatized carbohydrate group of the CD4 antigen and
an amino group of the gelsolin moiety or by introducing a free cysteine
into the CD4 antigen for crosslinking via thiol-specific reagents is
demonstrated.
Bibliographic Information
Liver-targetted positively-charged drug-comprising liposomes. Eibl,
Hansjoerg; Unger, Clemens. (Max-Planck-Gesellschaft zur Foerderung der
Wissenschaften e.V., Germany). Ger. Offen. (1991), 12 pp. CODEN:
GWXXBX DE 4013632 A1 19911031 Patent written in German.
Application: DE 90-4013632 19900427. CAN 116:158911 AN 1992:158911
CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
DE 4013632 A1 19911031 DE 1990-4013632 19900427
CA 2081119 AA 19911028 CA 1991-2081119 19910425
WO 9116880 A1 19911114 WO 1991-EP796 19910425
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD,
SU, US
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU,
ML, MR, NL, SE, SN, TD, TG
AU 9177702 A1 19911127 AU 1991-77702 19910425
AU 643282 B2 19931111
EP 526531 A1 19930210 EP 1991-908541 19910425
EP 526531 B1 19940622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 05506661 T2 19930930 JP 1991-508158 19910425
ES 2056648 T3 19941001 ES 1991-908541 19910425
Priority Application Information
DE 1990-4013632 19900427
WO 1991-EP796 19910425
Abstract
Liposomes suitable for drug targetting to the liver comprise the
pos.-charged glycerides R1OCH2CH(OR2)(CHOR)nCH2R3 [R1 = C14-18 alkyl or
alkoyl, oleoyl, oleyl; R2 = R1, P(O)(O-)OCH2CH2N+Me2CH2CH2N+Me3 (PNN) or
C(O)CH2CH2A+ (Gly); A = N+H3, N+H2Me, N+HMe2, N+Me3; R3 = OR1, OPNN, OGly,
A; R = R1, R2 or R3; n = 0, 1-3]. Macrophage-activating factor-charged
liposomes were prepd., as usual, from a film made of a soln. of 5 mmol
1,2-dipalmitoyl-sn-glycero-3-phospho-sn-1-glycerol, 1 mmol
1,2-dihexadecyl-rac-glycero-3-phospho-N,N-dimethyl-(N',N',N'-trimethylamino)
ethylammonium chloride and 4 mmol cholesterol in 50 mL CH2Cl2.
Bibliographic Information
Reducing the side effects of a drug by antibody-targetting of antidotes.
Matsumura, Kenneth Naoyuki. (USA). PCT Int. Appl. (1990), 16 pp.
CODEN: PIXXD2 WO 9010460 A1 19900920 Designated States W: AU, BG, BR,
CA, DK, FI, HU, JP, KP, KR, LK, MC, MG, NO, RO, SD, SU. Designated States
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE, BF, BJ, CF, CG, CM, GA,
ML, MR, SN, TD, TG. Patent written in English. Application: WO
90-US1264 19900308. Priority: US 89-322209. CAN 114:136055 AN
1991:136055 CAPLUS (Copyright 2003 ACS)
Patent Family Information
Patent No. Kind Date Application No. Date
WO 9010460 A1 19900920 WO 1990-US1264 19900308
W: AU, BG, BR, CA, DK, FI, HU, JP, KP, KR, LK, MC, MG, NO, RO, SD, SU
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML,
MR, NL, SE, SN, TD, TG
AU 9053492 A1 19901009 AU 1990-53492 19900308
EP 464135 A1 19920108 EP 1990-905767 19900308
EP 464135 B1 19960626
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE
AT 139701 E 19960715 AT 1990-905767 19900308
CN 1046464 A 19901031 CN 1990-101328 19900310
CN 1032190 B 19960703
Priority Application Information
US 1989-322209 19890313
WO 1990-US1264 19900308
Abstract
Drug antidotes are attached to antibodies which have affinity to cells
which are not the drug target, therefore reducing the side effects of the
drug. Attachment of the antibodies is preferably by way of liposomes. The
antidotes are folinic acid, thymidine, deoxycytidine, uridine, etc.
Unilamellar liposomes contg. Na folinate are made, using egg
phosphatidylcholine, cholesterol, and dipalmitoylphosphatidylethanolamine
3-(2-pyridyldithio)propionate (64:35:1 mol. ratio). To the lipsosomes were
bound antibodies with affinity to bone marrow precursors of white blood
corpuscles, using the method of J. Barbet, et al. (1981). The product,
injected i.v. prior to methotrexate administration in cancer treatment,
reduced the toxicity of methotrexate to the bone marrow.
Bibliographic Information
The use of targetted liposomes to isolate cells bearing immunoglobulin
receptors. Golubev, A.; Sidorova, E. Lab. Immunoglobulin Biosynth.,
Moscow Res. Inst. Viral Preparations, Moscow, USSR. Journal of
Immunological Methods (1989), 125(1-2), 29-34. CODEN: JIMMBG ISSN:
0022-1759. Journal written in English. CAN 112:136918 AN
1990:136918 CAPLUS (Copyright 2003 ACS)
Abstract
A new method of mouse B cell isolation has been developed. It is based on
the differences in buoyant d. of free lymphocytes and cells bound within
liposome-cellular complexes (LCC). LCC arise during the interaction of B
cells bearing surface Ig, with liposomes loaded with affinity purified
rabbit antibodies to mouse IgM/IgG. Advantage was taken of the fact that
LCC can be selectively removed from other cell populations by differential
flotation in Ficoll gradients. Because of their lower d. the LCC did not
sediment under conditions where free lymphocytes and complexes of the
liposomes with dead or damaged lymphocytes did sediment. The method was
highly specific and the recovery of B cells was .apprx.50%. B cells
isolated with the use of targetted liposomes retained viability and
functional activity. Theor., liposomes loaded with antibodies to any cell
surface marker could be used for the isolation of cells bearing such
markers.
Bibliographic Information
Advances in targetting drug delivery with immunoliposomes. Nie,
Songqing. Dep. Physicochem., Beijing Med. Univ., Beijing, Peop. Rep.
China. Shengli Kexue Jinzhan (1988), 19(2), 114-20. CODEN: SLKHA8
ISSN: 0559-7765. Journal; General Review written in Chinese. CAN
109:196949 AN 1988:596949 CAPLUS (Copyright 2003 ACS)
Abstract
A review, with 32 refs., of the prepn., pharmacokinetic, and application of
immunoliposomes (antibody-encapsulated liposomes) in targetting drug
delivery.
Bibliographic Information
Amino conjugates of a phosphatidylglycerol oxidation product: novel
adjuncts for liposome preparation. Campbell, Philip I. Dep.
Biochem., Univ. Benin, Benin, Nigeria. Medical Hypotheses (1984),
15(2), 149-53. CODEN: MEHYDY ISSN: 0306-9877. Journal written in
English. CAN 102:32136 AN 1985:32136 CAPLUS (Copyright 2003 ACS)
Abstract
NH2 groups in amino acids, proteins and possibly glycoproteins could be
conjugated to the product of periodate oxidn. of phosphatidylglycerol. The
reaction yields an unstable Schiff base, which could be converted to a more
stable phosphatidylethanol deriv. of the resp. amino acid or protein, by a
reducing agent, such as NaBH4. Such derivs. may be a useful alternative to
stearylamine in the prepn. of cationic liposomes for use in enzyme
replacement and drug therapy. They may be useful in prepg. liposomes with
stable glycoprotein and protein moieties projecting from the surface of the
vesicle, an important development in the effort to achieve selective homing
or targetting of liposomally entrapped therapeutic agents to specific
tissues.
Bibliographic Information
Studies on the methodology of the carboxyfluorescein assay and on the
mechanism of liposome stabilization by red blood cells in vitro.
Lelkes, Peter I.; Tandeter, Howard B. Dep. Membr. Res., Weizmann Inst.
Sci., Rehovot, Israel. Biochimica et Biophysica Acta (1982), 716(3),
410-19. CODEN: BBACAQ ISSN: 0006-3002. Journal written in English.
CAN 97:106488 AN 1982:506488 CAPLUS (Copyright 2003 ACS)
Abstract
The stability of small unilamellar liposomes was investigated in human in
vitro. By using the carboxyfluorescein technique, interaction between the
dye, the detergent Triton X 100, and an as yet unidentified component of
human serum, grossly interferes with the expt. and necessitates the use of
other detergents, preferably Na deoxycholate. Sepn. of liposomes and blood
cells by centrifugation induces a small leakage from the liposomes and can
lead to an underestn. of the real liposome stability. Upon incubation with
whole blood, intact liposomes are adsorbed nonspecifically to erythrocytes
and internalized by leukocytes, the extent and kinetics of the former
process being insensitive to the presence of metabolic inhibitors. The
stability of liposomes is enhanced significantly in whole blood or in serum
contg. washed erythrocytes. Similarly, liposome stability in serum could
be augmented by presaturating the serum lipoproteins with excess
phospholipid. Stable liposomes with high affinities for certain blood-cell
components may be developed as suitable carrier systems for drug targetting
in pathol. disorders within the blood stream.
Bibliographic Information
Potential applications of radionuclide-labeled liposomes in the detection
of the lymphatic spread of cancer. Osborne, M. P.; Richardson, V. J.;
Jeyasingh, K.; Ryman, B. E. Med. Sch., Charing Cross Hosp., London,
UK. International Journal of Nuclear Medicine and Biology (1982),
9(1), 47-51. CODEN: IJNMCI ISSN: 0047-0740. Journal written in
English. CAN 97:87931 AN 1982:487931 CAPLUS (Copyright 2003 ACS)
Abstract
The regional lymph node localization of 99mTc labeled liposomes in Rd/3
tumor-bearing rats, following interstitial injection, was studied by
external .gamma.-camera imaging and tissue radioassay. Normal and control
animals with either irradiated nonmetastasing Rd/3 tumor cells or
inflammation induced by Freund's adjuvant were also studied. 99mTc-labeled
neutral liposomes exhibited a marked inhibition of uptake by lymph nodes
partially replaced by Rd/3 metastatic tumor, an enhanced uptake was obsd.
in the presence of nonmetastasising tumor cells in the regional field when
compared to normal. In contrast 99Tc-labeled cationic liposomes showed a
less marked suppression of uptake by lymph nodes contg. metastases. Thus,
radiolabeled liposomes may be of value as a diagnostic test in the
detection of the lymphatic spread of cancer as well as acting as an in vivo
test of immunol. function in regional lymph nodes. The uptake of cationic
liposomes by lymph nodes bearing metastases suggest the targetting of this
agent as a therapeutic carrier to diseased lymph nodes.
Bibliographic Information
Targetting of liposomes. Finkelstein, Morris C.; Weissmann, Gerald.
Sch. Med., New York Univ., New York, NY, USA. Research Monographs in
Cell and Tissue Physiology (1981), 7(Liposomes: Phys. Struct. Ther.
Appl.), 443-64. CODEN: RMTPD8 ISSN: 0378-6129. Journal; General Review
written in English. CAN 96:149020 AN 1982:149020 CAPLUS
(Copyright 2003 ACS)
Abstract
A review with 114 refs. of the targetting of drug-carrying liposomes to
specific tissues.
Bibliographic Information
Immunologic targetting of liposomes. Leserman, L. D. Cent. Immunol.,
INSERM, Marseille, Fr. Editor(s): Nicolau, Claude; Paraf, Alain.
Liposomes, Drugs Immunocompetent Cell Funct., [Proc. Conf.] (1981),
Meeting Date 1980, 109-22. Publisher: Academic, London, Engl CODEN:
46WYA6 Conference; General Review written in English. CAN 96:50162
AN 1982:50162 CAPLUS (Copyright 2003 ACS)
Abstract
A review with 34 refs. The insertion of antibodies into liposomes and
subsequent binding to cell determinants are considered.
Bibliographic Information
The fate in vivo of liposomally-entrapped drugs in pregnant rats.
Tuzel, Nilden S.; Patel, Harish M.; Ryman, Brenda E. Dep. Biochem.,
Charing Cross Hosp. Med. Sch., London, UK. Biochemical Society
Transactions (1980), 8(5), 559-60. CODEN: BCSTB5 ISSN: 0300-5127.
Journal written in English. CAN 94:95634 AN 1981:95634 CAPLUS
(Copyright 2003 ACS)
Abstract
Cholesterol-3H-labeled liposomes contg. 14C-labeled inulin or penicillin
[1406-05-9] were injected i.v. (30-40 mg of lipids as liposomes/rat) into
rats in the 2nd half of gestation; the uptake of entrapped inulin or
penicillin was several fold greater in uterus and placenta than that of
free drugs. Neg. liposomes were localized more in these tissues than
neutral liposomes, and neutral liposomes more than pos. ones. Nonsonicated
neg. liposomes were poorly taken up by the uterus and placenta. Fluid
liposomes were more readily localized in placenta than were solid
liposomes. There was a 2- to 3-fold increase in entrapped penicillin in
the fetus and amniotic fluid compared to free penicillin, whereas inulin
was not present in these tissues. Liposomes may break down the placenta so
that free penicillin crosses the placental barrier. Thus, liposomes may be
useful as drug carriers for targetting therapeutic agents, e.g. antibiotics
or antimitotic agents, to uterine and placental tissues and to the fetus.
Bibliographic Information
Disposition kinetics of ketotifen from liposomal dry powder for inhalation
in rat lung. Joshi Mayank; Misra Ambikanandan Pharmacy Department,
Faculty of Technology and Engineering, Kalabhavan, MS University of Baroda,
Baroda, Gujarat, India CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND
PHYSIOLOGY (2003 Mar), 30(3), 153-6. Journal code: 0425076.
ISSN:0305-1870. Journal; Article; (JOURNAL ARTICLE) written in English.
DN 22492000 PubMed ID 12603343 AN 2003092315 In-process for MEDLINE
(Copyright 2003 U.S. National Library of Medicine)
Abstract
1. The aim of the present study was to understand the benefit of liposomal
dry powder for inhalation (LDPI) of ketotifen fumarate (KF) over plain drug
dry powder for inhalation as a pulmonary targetted drug-delivery system. 2.
The KF liposomes, composed of egg phosphatidyl choline and cholesterol,
were prepared by the lipid film hydration technique. The liposomal
dispersion was freeze dried and formulated to a dry powder for inhalation.
Values of 89.0-65.3% drug entrapment of freeze-dried liposomes were
estimated in prepared batches. 3. Rehydrated KF liposomes formed by the
hydration of LDPI or the plain KF solution was delivered to rat lungs by
intratracheal instillation. Simultaneous monitoring of drug levels in the
bronchoalveolar lavage and lung tissue enabled assessment of pulmonary drug
disposition. 4. Cumulative drug levels in lung tissue after intratracheal
administration revealed that with liposomes targetting factors were between
1.36 and 1.54. The maximal drug concentration in lung homogenate for LDPI
was 42.0 micro g compared with 73.6 micro g for plain drug solution. 5.
Similarly, the time to reach maximum drug concentration in the lung
homogenate for liposomal dry powder was 9-12 h compared with 3 h for plain
drug. 6. Hence, the use of LDPI of KF was found to provide desired drug
levels in the lung for a long time and thereby increased pulmonary
targetting 7. This is expected to enhance the therapeutic index of the
drug and probably reduce the dose administered and the cost of therapy.
Bibliographic Information
Polyethylene glycol in the design of tumor-targetting radiolabelled
macromolecules -- lessons from liposomes and monoclonal antibodies.
Harrington K J; Mubashar M; Peters A M Cancer Research UK Laboratory of
Targetted Therapy Centre for Cell and Molecular Biology, Institute of
Cancer Research, London, UK. kevinh@icr.ac.uk QUARTERLY JOURNAL OF
NUCLEAR MEDICINE (2002 Sep), 46(3), 171-80. Journal code: 9512274.
ISSN:1125-0135. Journal; Article; (JOURNAL ARTICLE); General Review;
(REVIEW); (REVIEW, TUTORIAL) written in English. DN 22129490 PubMed ID
12134134 AN 2002385465 MEDLINE (Copyright 2003 U.S. National Library of
Medicine)
Abstract
Radiolabelled macromolecules such as liposomes and monoclonal antibodies
(Mab) are attractive agents for tumour-targetting studies. In addition to
their potential diagnostic role, they can also provide vital information on
the targetting capacity of therapeutic agents. Certainly in the case of
liposome development, this ability to track the pharmacokinetics and
biodistribution of the agents in a non-invasive fashion has assisted the
design and application of therapeutic liposomal agents. A significant
limitation of unmodified liposomes and Mab is their tendency to be cleared
rapidly from the circulation. The use of polyethylene glycol (PEG) in the
formulation of these agents has the capacity to alter their biological
behaviour in such a way as to improve their ability to target tumours. In
this paper we review the data relating to the use of PEG-modified liposomes
and Mab in the context of nuclear medicine studies.
Bibliographic Information
In vivo myocardial gene transfer: optimization, evaluation and direct
comparison of gene transfer vectors. Wright M J; Wightman L M; Lilley
C; de Alwis M; Hart S L; Miller A; Coffin R S; Thrasher A; Latchman D S;
Marber M S Department of Cardiology, KCL, The Rayne Institute, St
Thomas' Hospital, London, England BASIC RESEARCH IN CARDIOLOGY (2001
May-Jun), 96(3), 227-36. Journal code: 0360342. ISSN:0300-8428.
(EVALUATION STUDIES); Journal; Article; (JOURNAL ARTICLE) written in
English. DN 21296075 PubMed ID 11403416 AN 2001335093 MEDLINE
(Copyright 2003 U.S. National Library of Medicine)
Abstract
The purpose was to determine the relative efficiency, toxicity and duration
of expression following gene delivery by intramyocardial injection of naked
DNA, naked DNA complexed to cationic liposomes, naked DNA complexed to
cationic liposomes with integrin-targetting peptide, recombinant (E1-/E3-)
adenovirus, recombinant adeno-associated virus and recombinant (ICP27-)
herpes simplex virus. All vectors incorporated a LacZ reporter driven by a
promoter containing the hCMV-IE promoter/enhancer. Efficiency was scored
by counting positive cells in five standard microscopic sections harvested
from the left ventricular apex. Rabbit hearts (n = 100) were |
Forum 
